MycoShell
A living, radiation-shielding structural habitat shell grown from local regolith. TRL 4; component-level lab and flight data exists and system integration is underway.
The opportunity
Crewed missions to the Moon and Mars are moving from design into hardware.
Radiation protection, habitat structure and crew health have no flight-qualified answer yet. That is the gap Aeginis is built to fill.
Market
Two markets, one grown material
Third-party estimates: Space Medicine Global Market Report 2026 (Research and Markets), 12.5% CAGR 2026-2030; mycelium-based building materials market reports 2026-2035, 12.15% CAGR. Estimates vary by publisher.
2019-20
ISS flight experiment
A melanized fungus flown to the ISS attenuates radiation: first direct evidence a living organism can shield in space.
Now
NASA NIAC Phase III
NASA myco-architecture advances to Phase III with testing at Brookhaven National Laboratory.
2028-30s
Artemis and Mars concepts
Artemis lunar surface missions and early crewed Mars concepts move from design into hardware, creating near-term buyers.
Aeginis
First engineering
Fusing radiotrophic biology with grown habitat structure into one flight-qualified product.
What we are building
Three platforms, one company.
Crew-health biology
Fourteen shelf-stable probiotic, peptide, exosome and nutrition products, staged from concept to in-development, designed to work without refrigeration.
Cosmion
A computational biology platform: cited evidence, strain safety, peptide design and mission simulation, with uncertainty on every prediction and a published validation plan.
Why Aeginis
A white space nobody has built a company in.
Radiotrophic biology and grown mycelium structure are each validated on their own. Combining them into one space-native, multi-function product is the position we occupy.
01
One organism, three jobs
Shield, structure and water and waste processing from a single strain: one materials-biology programme instead of three high-risk biologics, with lower regulatory risk and one supply chain.
02
Non-dilutive path to flight
Milestone-based agency contracts fund the ISS structural demonstration, building on NASA's own NIAC investment in the underlying science.
03
Terrestrial upside
The grown mycelium composite can be licensed into sustainable construction with no space contract required, so value does not depend on agency timelines.
04
Decision-grade R&D
Cosmion ranks every product on evidence, technical risk, cost to test, regulatory path and mission relevance, so capital goes to the experiments that teach us most.
Business model
Three revenue streams.
01
Agency contracts
Milestone-based development and flight-demo contracts with space agencies, building on NASA's own NIAC investment in the underlying science.
02
Habitat licensing
Recurring licensing of structural-shell and shielding material to commercial LEO stations and lunar module builders.
03
Terrestrial materials
Out-licensing the grown mycelium composite into sustainable construction, with no space contract required.
Milestones
What the next three years deliver.
MycoShell
Coupon, orbit, pilot
Year 1
Year 2
Year 3+
MycoShell
Ground and small orbital coupon tests
ISS National Lab structural and shielding demo
Lunar Gateway or commercial station pilot
Radioprotective probiotic
Parked at TRL 1: advances only if MycoShell milestones are funded ahead of schedule
Cosmion
Platform phases
Phase 1
Phase 2
Phase 3
Phase 4
Cosmion
Evidence and ranking
Strains and peptides
Simulation and planning
Closed loop
Risks
What we manage, openly.
| Risk | How we address it |
|---|---|
| Scaling from coupons to full panels | Staged coupon, subscale and full-scale testing at Brookhaven and on the ISS before any lunar pilot. |
| Growth in microgravity | Early ground and parabolic-flight testing across gravity regimes before any crewed-habitat commitment. |
| Slow agency procurement | Terrestrial licensing track diversifies revenue away from agency timing. |
| Regulatory path for biologics | Materials-science route for the flagship; biologic programmes are staged and kept behind it. |
How to engage
From first call to diligence.
Introduce yourself
Tell us about your fund or organisation and your interest using the form below, or call us.
Overview call
A conversation with the founding team about the science, the roadmap and the stage of each programme.
Investor materials
We share detailed materials, including the investor presentation, under a non-disclosure agreement.
Diligence
Technical and commercial due diligence, including data on testing to date and the Cosmion validation plan.
Investor enquiries
Start the conversation.
Venture capital, angel, family office, corporate and government funding partners are all welcome.
This page is for information only. It is not an offer or solicitation to sell or buy securities in any jurisdiction. Statements about plans, timelines and markets are forward-looking, depend on testing and funding, and may change. Market figures are third-party estimates. All Aeginis products are under research and development, not approved by any regulator and not available for sale.